MEDX HEALTH CORP (MDX.CA) Fundamental Analysis & Valuation
TSX-V:MDX • CA5850901037
Current stock price
0.055 CAD
0 (0%)
Last:
This MDX.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. MDX.CA Profitability Analysis
1.1 Basic Checks
- In the past year MDX has reported negative net income.
- In the past year MDX has reported a negative cash flow from operations.
- In the past 5 years MDX always reported negative net income.
- MDX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -422.39%, MDX is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -422.39% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-597.39%
ROA(5y)-591.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- MDX has a Gross Margin of 33.60%. This is in the lower half of the industry: MDX underperforms 66.67% of its industry peers.
- MDX's Gross Margin has declined in the last couple of years.
- MDX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 33.6% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.51%
GM growth 5Y-6.59%
2. MDX.CA Health Analysis
2.1 Basic Checks
- MDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, MDX has more shares outstanding
- Compared to 5 years ago, MDX has more shares outstanding
- MDX has a better debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -78.59, we must say that MDX is in the distress zone and has some risk of bankruptcy.
- MDX has a Altman-Z score of -78.59. This is in the lower half of the industry: MDX underperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -78.59 |
ROIC/WACCN/A
WACC7.66%
2.3 Liquidity
- A Current Ratio of 0.10 indicates that MDX may have some problems paying its short term obligations.
- With a Current ratio value of 0.10, MDX is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
- A Quick Ratio of 0.06 indicates that MDX may have some problems paying its short term obligations.
- MDX has a Quick ratio of 0.06. This is in the lower half of the industry: MDX underperforms 73.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.1 | ||
| Quick Ratio | 0.06 |
3. MDX.CA Growth Analysis
3.1 Past
- MDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -54.10%.
- The Revenue has grown by 42.09% in the past year. This is a very strong growth!
- MDX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -10.66% yearly.
EPS 1Y (TTM)-54.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65.38%
Revenue 1Y (TTM)42.09%
Revenue growth 3Y-4.55%
Revenue growth 5Y-10.66%
Sales Q2Q%49.34%
3.2 Future
- Based on estimates for the next years, MDX will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.33% on average per year.
- The Revenue is expected to grow by 187.43% on average over the next years. This is a very strong growth
EPS Next Y-50.36%
EPS Next 2Y-22.62%
EPS Next 3Y19.33%
EPS Next 5YN/A
Revenue Next Year14.21%
Revenue Next 2Y170%
Revenue Next 3Y187.43%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. MDX.CA Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for MDX. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- MDX's earnings are expected to grow with 19.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.62%
EPS Next 3Y19.33%
5. MDX.CA Dividend Analysis
5.1 Amount
- MDX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MDX.CA Fundamentals: All Metrics, Ratios and Statistics
TSX-V:MDX (4/28/2026, 7:00:00 PM)
0.055
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Industry Strength18.11
Industry Growth24.63
Earnings (Last)12-01 2025-12-01
Earnings (Next)05-05 2026-05-05
Inst Owners0.01%
Inst Owner ChangeN/A
Ins Owners26.75%
Ins Owner ChangeN/A
Market Cap18.04M
Revenue(TTM)522.90K
Net Income(TTM)-5.30M
Analysts84.44
Price Target0.29 (427.27%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-37.78%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 34.49 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.02
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -422.39% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 33.6% | ||
| FCFM | N/A |
ROA(3y)-597.39%
ROA(5y)-591.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.51%
GM growth 5Y-6.59%
F-Score3
Asset Turnover0.42
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.1 | ||
| Quick Ratio | 0.06 | ||
| Altman-Z | -78.59 |
F-Score3
WACC7.66%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-54.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65.38%
EPS Next Y-50.36%
EPS Next 2Y-22.62%
EPS Next 3Y19.33%
EPS Next 5YN/A
Revenue 1Y (TTM)42.09%
Revenue growth 3Y-4.55%
Revenue growth 5Y-10.66%
Sales Q2Q%49.34%
Revenue Next Year14.21%
Revenue Next 2Y170%
Revenue Next 3Y187.43%
Revenue Next 5YN/A
EBIT growth 1Y-28.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.8%
OCF growth 3YN/A
OCF growth 5YN/A
MEDX HEALTH CORP / MDX.CA Fundamental Analysis FAQ
What is the fundamental rating for MDX stock?
ChartMill assigns a fundamental rating of 1 / 10 to MDX.CA.
Can you provide the valuation status for MEDX HEALTH CORP?
ChartMill assigns a valuation rating of 0 / 10 to MEDX HEALTH CORP (MDX.CA). This can be considered as Overvalued.
What is the profitability of MDX stock?
MEDX HEALTH CORP (MDX.CA) has a profitability rating of 0 / 10.
Can you provide the financial health for MDX stock?
The financial health rating of MEDX HEALTH CORP (MDX.CA) is 0 / 10.